Drug Search Results
More Filters [+]

EMB-01

Alternative Names: emb-01, emb01, emb 01
Latest Update: 2024-08-26
Latest Update Note: Clinical Trial Update

Product Description

EMB-01 is a novel bispecific antibody developed based on EpimAbÕs proprietary FIT-Ig¨ platform to simultaneously target EGFR and cMet on tumor cells. The resulting highly potent and durable anti-tumor effect in animal models encouraged EpimAb to rapidly advance EMB-01 to the clinic where it is currently being investigated in oncology indications. (Sourced from: https://www.epimab.com/en/news/11)

Mechanisms of Action: EGFR Inhibitor,C-Met Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shanghai EpimAb Biotherapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EMB-01

Countries in Clinic: China, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Carcinoid Tumor|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

EMB01X201

P2

Recruiting

Gastrointestinal Cancer|Carcinoid Tumor

2025-12-31

EMB01X101

P2

Recruiting

Non-Small-Cell Lung Cancer

2025-03-14

57%

EMB01X202

P2

Not yet recruiting

Non-Small-Cell Lung Cancer

2024-07-01

57%

Recent News Events